WaferGen Bio-systems, Inc. engages in the development, manufacture, and sale of systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Europe, and Asia. The company is primarily focused on marketing a flexible, open format genetic analysis system, the WaferGen SmartChip System, which provides a range of high throughput capabilities including mRNA, microRNA and lncRNA expression level measurement, as well as SNP genotyping. In July 2012, the company launched the SmartChip MyDesign System, which is the second-generation instrument with significantly upgraded capabilities. The SmartChip System’s high density, nanoliter-scale format can provide throughput levels that facilitate the development of life science clinical research solutions at a fraction of the time and cost currently possible with existing competing systems. Products SmartChip System The company’s SmartChip System provides a suite of gene expression and genome analysis technologies enabling both biomarker discovery and validation on a single platform with the sensitivity of real-time polymerase chain reaction (PCR). The company’s SmartChip Real-Time PCR System consists of two instrumentation components: a SmartChip MultiSample Nanodispenser (MSND) for applying sample, assay and reaction mix to the SmartChip Panels, and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. For large studies, its SmartChips are provided with sub-nanoliter (one-billionth of a liter) oligoneucleotide5 reagents of the customer’s choosing pre-loaded in the wells. For smaller projects, the user has the flexibility to purchase empty SmartChips and both samples and assays can be dispensed into the SmartChips at the customer’s site using the MSND. The company’s SmartChip Panels are designed with evaporation control measures that allow for the use of nanoliter volumes, thermal cycling and temperature control. The company’s software system also analyzes the high throughput data after the completion of the real-time PCR analysis. SmartChip Target Enrichment (TE) System The concept of the SmartChip TE System is to use the SmartChip consumable for amplifying the targets of interest via PCR and then remove the resulting amplified material for further processing prior to sequencing. By having individual PCR reactions, the SmartChip TE System offers a controlled chemo-enzymatic process that might ultimately translate into sequencing results. Market Applications of the SmartChip System Biomarker Discovery and Validation: New targets for drugs can be identified through the analysis of gene profile expression (biomarkers) in diseased cells. Potential applications include cancers, arthritis, and lung diseases. Drug Efficacy and Optimization: Genetic analysis is being used to determine the likely toxicity (toxicogenomics) of new drugs and the likelihood of therapeutic response to a specific genetic profile (pharmacogenomics). Drug Response Monitoring: Patient outcomes can be improved by evaluation of a proposed drug’s potency and specificity in order to determine individualized patient dosing, thereby decreasing adverse drug reactions, and improving drug efficacy. Detection of Rare Mutations: The Cancer Genome Project is using the human genome sequence and high throughput mutation detection techniques to identify somatically acquired sequence variants/mutations and hence identify genes critical in the development of human cancers. Research and Development The company’s research and development activities are aimed at developing new products and new applications, improving existing products, improving product quality and reducing production costs. The company’s research and development expenses were approximately $6.16 million for the period ended December 31, 2012. Intellectual Property and Other Proprietary Rights The company has four patents issued and five pending in the U.S. with respect to its SmartChip products and technologies, and other pending SmartChip-related patent applications worldwide. Competition The company’s competitors include LIFE, Affymetrix, Inc., Fluidigm Corporation and Illumina. History WaferGen Bio-systems, Inc. was founded in 2002.
wafergen bio-systems inc
(WGBS:OTC Markets Group Inc - OTCQB)
7400 Paseo Padre Parkway
Fremont, CA 94555
|No competitor information is available for WGBS.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact WAFERGEN BIO-SYSTEMS INC, please visit www.wafergen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.